Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · June 17, 2019

Trabectedin or Dacarbazine in Patients With Advanced Liposarcoma or Leiomyosarcoma

Cancer

 

Additional Info

Cancer
Overall Survival and Histology-Specific Subgroup Analyses From a Phase 3, Randomized Controlled Study of Trabectedin or Dacarbazine in Patients With Advanced Liposarcoma or Leiomyosarcoma
Cancer 2019 Jun 07;[EPub Ahead of Print], S Patel, M von Mehren, DR Reed, P Kaiser, J Charlson, CW Ryan, D Rushing, M Livingston, A Singh, R Seth, C Forscher, G D'Amato, SP Chawla, S McCarthy, G Wang, T Parekh, R Knoblauch, ML Hensley, RG Maki, GD Demetri

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading